Literature DB >> 17128428

Sample size and the probability of a successful trial.

Christy Chuang-Stein1.   

Abstract

This paper describes the distinction between the concept of statistical power and the probability of getting a successful trial. While one can choose a very high statistical power to detect a certain treatment effect, the high statistical power does not necessarily translate to a high success probability if the treatment effect to detect is based on the perceived ability of the drug candidate. The crucial factor hinges on our knowledge of the drug's ability to deliver the effect used to power the study. The paper discusses a framework to calculate the 'average success probability' and demonstrates how uncertainty about the treatment effect could affect the average success probability for a confirmatory trial. It complements an earlier work by O'Hagan et al. (Pharmaceutical Statistics 2005; 4:187-201) published in this journal. Computer codes to calculate the average success probability are included.

Mesh:

Year:  2006        PMID: 17128428     DOI: 10.1002/pst.232

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  14 in total

1.  Using local multiplicity to improve effect estimation from a hypothesis-generating pharmacogenetics study.

Authors:  W Zou; H Ouyang
Journal:  Pharmacogenomics J       Date:  2015-03-24       Impact factor: 3.550

2.  Sample size determination in bioequivalence studies using statistical assurance.

Authors:  A Ring; B Lang; C Kazaroho; D Labes; R Schall; H Schütz
Journal:  Br J Clin Pharmacol       Date:  2019-08-13       Impact factor: 4.335

3.  Estimation of treatment effect for the sequential parallel design.

Authors:  Roy N Tamura; Xiaohong Huang; Dennis D Boos
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

4.  Bayesian probability of success for clinical trials using historical data.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; Mani Lakshminarayanan; Guanghan F Liu; Joseph F Heyse
Journal:  Stat Med       Date:  2014-10-23       Impact factor: 2.373

5.  A two-stage approach for combining gene expression and mutation with clinical data improves survival prediction in myelodysplastic syndromes and ovarian cancer.

Authors:  Yan Li; Xinyan Zhang; Tomi Akinyemiju; Akinyemi I Ojesina; Jeff M Szychowski; Nianjun Liu; Bo Xu; Nengjun Yi
Journal:  J Bioinform Genom       Date:  2016-09-15

6.  Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.

Authors:  Joy M Schmitz; Scott D Lane; Michael F Weaver; Ponnada A Narayana; Khader M Hasan; DeLisa D Russell; Robert Suchting; Charles E Green
Journal:  Contemp Clin Trials       Date:  2021-10-22       Impact factor: 2.226

7.  Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.

Authors:  Maria M Ciarleglio; Christopher D Arendt
Journal:  Trials       Date:  2017-02-23       Impact factor: 2.279

8.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Authors:  Andrew Satlin; Jinping Wang; Veronika Logovinsky; Scott Berry; Chad Swanson; Shobha Dhadda; Donald A Berry
Journal:  Alzheimers Dement (N Y)       Date:  2016-02-04

9.  The statistical interpretation of pilot trials: should significance thresholds be reconsidered?

Authors:  Ellen C Lee; Amy L Whitehead; Richard M Jacques; Steven A Julious
Journal:  BMC Med Res Methodol       Date:  2014-03-20       Impact factor: 4.615

10.  Assurance calculations for planning clinical trials with time-to-event outcomes.

Authors:  Shijie Ren; Jeremy E Oakley
Journal:  Stat Med       Date:  2013-07-16       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.